- Comparisons of survival after propensity score matching based on clinicopathological characteristics between the non-pathological complete response and pathological complete response groups of elderly women with triple-negative invasive ductal breast cancer after neoadjuvant chemotherapy.
| Characteristics | Non-pathological complete response (n=181) | Pathological complete response (n=97) | P-values |
|---|---|---|---|
| Age, years | |||
| 70-74 | 104 (57.5) | 55 (56.7) | 0.638 |
| 75-79 | 53 (29.3) | 28 (28.9) | |
| 80-84 | 14 (7.7) | 11 (11.3) | |
| ≥85 | 10 (5.5) | 3 (3.0) | |
| Race | |||
| White | 123 (68.0) | 73 (75.3) | 0.571 |
| Black | 31 (17.1) | 14 (14.4) | |
| Asian or Pacific Islander | 21 (11.6) | 9 (9.3) | |
| American Indian/Alaska Native | 6 (3.3) | 1 (1.0) | |
| SEER summary stage | |||
| Local involvement | 77 (42.5) | 45 (46.4) | 0.988 |
| Direct spread | 10 (5.5) | 5 (5.2) | |
| Regional lymph node involvement | 64 (35.4) | 32 (33.0) | |
| Direct spread and regional lymph node involvement | 24 (13.3) | 12 (12.4) | |
| Distant metastasis | 6 (3.3) | 3 (3.1) | |
| TNM | |||
| I | 24 (13.3) | 15 (15.5) | 0.961 |
| II | 107 (59.1) | 57 (58.8) | |
| III | 46 (25.4) | 23 (23.7) | |
| IV | 4 (2.2) | 2 (2.1) | |
| Tumor location | |||
| Center | 8 (4.4) | 4 (4.1) | 0.643 |
| Axillary tail | 1 (0.5) | 0 (0.0) | |
| Lower outer quadrant | 20 (11.0) | 6 (6.2) | |
| Upper outer quadrant | 67 (37.0) | 33 (34.0) | |
| Lower inner quadrant | 11 (6.1) | 11 (11.3) | |
| Upper inner quadrant | 16 (8.8) | 8 (8.2) | |
| Overlapping region | 42 (23.2) | 23 (23.7) | |
| Unknown region | 16 (8.8) | 12 (12.4) | |
| Surgery, yes | 176 (97.2) | 97 (100) | 0.239 |
| Disease-specific survival, yes | 117 (64.6) | 86 (88.7) | <0.001 |
| Overall survival, yes | 155 (85.6) | 86 (88.7) | 0.601 |
Values are presented as numbers and percentages (%). Statistical tests were either Chi-square test (all categories with % ≥5) or Fisher-Freeman-Halton test (for multiple categorical variables that did not satisfy Chi-square test conditions). SEER: surveillance, epidemiology, and end results, TNM: tumor, node, and metastasis